The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
Abstract
There is currently no universally accepted numbering convention for the antiviral drug-related resistance mutations in the reverse transcriptase (rt) domain of the human hepatitis B virus (HBV) polymerase. The published inconsistencies have resulted from different HBV genotypes. A standardized numbering system for HBV polymerase is proposed. The new system is based on functional observations of HBV surface gene proteins (preS1, preS2, and HBsAg) and on the current convention used for human immunodeficiency virus type 1 (HIV-1) polymerase proteins (protease, rt, and integrase), in which the amino acid numbering restarts at the first codon position of each domain. The HBV polymerase protein can be divided into 4 domains (terminal protein, spacer, rt, ribonuclease H) and each of these can be numbered separately. In this proposal, the HBV rt domain starts with the highly conserved EDWGPCDEHG motif, contains 344 amino acids, and the lamivudine-related resistance mutations are found at amino acid rtL180M (previously amino acid 528, 526, 515, or 525) and rtM204V/I (previously 552, 550, 539, or 549). The new consensus rt domain numbering system is genotype independent and allows investigators to number any previously and newly discovered antiviral-related amino acid change in a standardized manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Huang, H., Chopra, R., Verdine, G. L., & Harrison, S. C. (1998) · Science · doi:10.1126/science.282.5394.1669 · Cited by 1,420
Identification of four conserved motifs among the RNA-dependent polymerase encoding elements.
Poch, O., Sauvaget, I., Delarue, M., & Tordo, N. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08565.x · Cited by 1,202
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Vaccine-induced escape mutant of hepatitis B virus
Carman, W. F., Karayiannis, P., Waters, J., Thomas, H. C., Zanetti, A. R., Manzillo, G., & Zuckerman, A. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91874-a · Cited by 1,074
Typing Hepatitis B Virus by Homology in Nucleotide Sequence: Comparison of Surface Antigen Subtypes
Okamoto, H., Tsuda, F., Sakugawa, H., SASTROSOEWIGNJO, R. I., Imai, M., Miyakawa, Y., & Mayumi, M. (1988) · Journal of General Virology · doi:10.1099/0022-1317-69-10-2575 · Cited by 1,057
Viral dynamics in hepatitis B virus infection.
Nowak, M. A., Bonhoeffer, S., Hill, A. M., Boehme, R., Thomas, H. C., & McDade, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4398 · Cited by 1,045
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli
Galibert, F., Mandart, E., Fitoussi, F., Tiollais, P., & Charnay, P. (1979) · Nature · doi:10.1038/281646a0 · Cited by 981
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
Kao, J., Chen, P., Lai, M., & Chen, D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70261-7 · Cited by 925
Weber, P. C., Lesburg, C. A., Cable, M., Ferrari, E., Hong, Z., & Mannarino, A. F. (1999) · Nature Structural Biology · doi:10.1038/13305 · Cited by 755
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Norder, H., Couroucé, A.-M., Coursaget, P., Echevarria, J. M., Lee, S.-D., Mushahwar, I. K., Robertson, B. H., Locarnini, S., & Magnius, L. O. (2004) · Intervirology · doi:10.1159/000080872 · Cited by 868
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Lok, A. S. F., & McMahon, B. J. (2001) · Hepatology · doi:10.1053/jhep.2001.29401 · Cited by 709
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Lai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 564
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., & Tobias, H. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.021 · Cited by 558
Molecular Virology of Hepatitis B Virus
Locarnini, S. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828672 · Cited by 515
Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J.-M., Liaw, Y.-F., Mizokami, M., & Kuiken, C. (2007) · Hepatology · doi:10.1002/hep.21698 · Cited by 447
Kramvis, A., Kew, M., & François, G. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.10.045 · Cited by 394
Hepatitis B viruses: Reverse transcription a different way
Nassal, M. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.024 · Cited by 382
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., Tobias, H., & Wright, T. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00312-4 · Cited by 359
van Bömmel, F., de Man, R. A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., Erhardt, A., Hüppe, D., Stein, K., Trojan, J., et al. (2010) · Hepatology · doi:10.1002/hep.23246 · Cited by 330
van Bömmel, F., Zöllner, B., Sarrazin, C., Spengler, U., Hüppe, D., Möller, B., Feucht, H.-H., Wiedenmann, B., & Berg, T. (2006) · Hepatology · doi:10.1002/hep.21253 · Cited by 287
Hepatitis B virus genetic variability and evolution
Kay, A., & Zoulim, F. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.021 · Cited by 278
Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications
Pollicino, T., Cacciola, I., Saffioti, F., & Raimondo, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.041 · Cited by 277
Management of chronic hepatitis B
Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00431-2 · Cited by 257
Evolution of multi-drug resistant hepatitis B virus during sequential therapy
Yim, H. J., Hussain, M., Liu, Y., Wong, S. N., Fung, S. K., & Lok, A. S. F. (2006) · Hepatology · doi:10.1002/hep.21290 · Cited by 253
Sung, J. J. Y., Wong, M.-L., Bowden, S., Liew, C.-T., Hui, A. Y., Wong, V. W. S., Leung, N. W. Y., Locarnini, S., & Chan, H. L. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.009 · Cited by 218
Menéndez-Arias, L., Sebastián-Martín, A., & Álvarez, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.12.019 · Cited by 123
Ghozy, S., Nam, N. H., Radwan, I., Karimzadeh, S., Tieu, T. M., Hashan, M. R., Abbas, A. S., Eid, P. S., Vuong, N. L., Khang, N. V., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2089 · Cited by 32
Vörös, J., Urbanek, A., Rautureau, G. J. P., O'Connor, M., Fisher, H. C., Ashcroft, A. E., & Ferguson, N. (2014) · Journal of Virology · doi:10.1128/jvi.02575-13 · Cited by 27
Metadata
- Authors
- Stuyver, L.
- Venue
- Hepatology
- Published
- 2001-03
- Volume
- 33
- Issue
- 3
- Pages
- 751-757
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2142861964
- Cited by
- 382
- References
- 29
- FWCI
- 26.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.